Loading patent…
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Fondation Imagine, Assistance Publique-HôPitaux De Paris (Aphp), Universite De Paris, Universite Toulouse III - Paul Sabatier
InventorsChantal Lagresle-Peyrou, Aurélien Olichon, Hanem Sadek-Rock, Isabelle Andre, Marina Cavazzana
Estimating the term…
The inventors have identified an autosomal dominant (AD) missense mutation in the RAC2 gene (coding for Ras-related botulinum toxin substrate 2 (RAC2)) in three Severe combined immunodeficiencies (SCID) patients whose clinical presentation overlaps with the RD SCID form but who lack AK2 mutations and deafness. Using biochemical and in vitro differentiation assays, the inventors demonstrated that the RAC2 mutation was closely related to an impairment in cell differentiation capacity and defects in cellular and mitochondrial networks. Taken as a whole, the data demonstrate that a dominant gain-of-function (GOF) mutation in the RAC2 protein's GDP/GTP binding site inhibits HSPC differentiation and leads to a severe AD form of SCID with a clinical presentation of RD. Accordingly, the results prompt to consider that introduction of the identified RAC2 mutein in the hematopoietic lineage would be suitable for inducing full ablation of hematopoiesis.
A method of treating acute myelogenous leukemia (AML) in a patient that has AML comprising administering to the patient a therapeutically effective amount of i) a polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:1 wherein the amino residue (G) at position 12 is mutated to R, or ii) a polynucleotide encoding for a polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:1 wherein the amino residue (G) at position 12 is mutated to R.
Dependencies are inferred from the claim text.